ArticleCell reports. Medicine2026
Predicting glioma survival and extracellular matrix remodeling through MRI radiogenomics.
Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular matrix (ECM) remodeling is essential for glioma invasion, yet lacks non-invasive assessment methods. This study employs radiogenomics to enable non-invasive survival prediction and ECM remodeling assessment in glioma. Utilizing a multi-dataset data (n = 891), an 11-feature radiomics signature is developed stratifying patients into low- and high-Rad-score groups (area under the receiver operator characteristic curve [AUC] = 0.886, 95% confidence interval [CI]: 0.807-0.964 in the training set from two local centers; AUC = 0.828, 95% CI: 0.796-0.893 in the validation set from five public datasets). Radiogenomic analysis (n = 572) reveals differentially expressed genes significantly associated with Rad-scores, particularly enriched in pathways associated with ECM remodeling, and identifies seven related hub genes (MMP2, MMP9, CXCL8, TIMP1, IL-6, COL1A2, and CCL2). These findings are validated using an external radiogenomic dataset and orthotopic (both syngeneic and xenograft) mouse models, where silencing MMP2 reduced Rad-scores and tumor infiltration. This study highlights the potential of MRI-based radiomics signatures in assessing ECM remodeling for survival prediction and improved glioma clinical management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.